Europlasma (1EZ0.F XETRA) down 15.56% 18 Feb 2026: market closed, liquidity risk

The 1EZ0.F stock slumped 15.56% on XETRA on 18 Feb 2026, closing the session at EUR 0.0293 as the market closed. Volume was thin at 40 shares versus an average of 5,461, amplifying price moves for Europlasma S.A. (1EZ0.F). Today’s decline pushed the share close to its year low of EUR 0.0286 and highlights ongoing liquidity and fundamental pressure in this waste management technology name.

1EZ0.F stock: price action and market context

Europlasma S.A. (1EZ0.F) traded between EUR 0.0284 and EUR 0.0312 today on XETRA, finishing at EUR 0.0293 after opening at EUR 0.0303. The one-day move of -15.56% contrasts with a 50-day average price of EUR 0.16449 and a 200-day average of EUR 6.49951, underlining extreme share depreciation over time.

Why shares fell today and sector influence

The drop follows persistent negative margins and weak liquidity; Europlasma’s TTM net profit margin is -36.02% and EPS is -90.70, which link directly to investor selling. The Industrials sector in Germany has outperformed on services and capital cycles, but Europlasma’s Waste Management niche shows higher volatility and lower investor appetite compared with sector peers.

Financials, valuation and Meyka AI grade

Europlasma reports TTM revenue per share 0.0419 and negative book value per share -0.0110, with enterprise value-to-sales at 0.27 and a negative PE. Meyka AI rates 1EZ0.F with a score out of 100: 62.87 (Grade B, SUGGESTION: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. These grades are not guarantees and are for informational purposes only.

Technicals, liquidity and short-term signals

Technically the stock is oversold: RSI 31.11, CCI -110.77 and Williams %R -97.43. Average daily volume is 5,461 but today’s volume was 40, producing a relative volume spike and thin-book risk. Low free cash flow per share -0.0128 and current ratio 0.77 increase short-term solvency concerns for traders on XETRA.

Analyst view, price target and Meyka AI forecast

Broker consensus data is limited; companyRating dated 17 Feb 2026 shows mixed signals and a composite rating of C (Sell) from one aggregator. Meyka AI’s forecast model projects a 12-month base target of EUR 0.0200, compared with the current price EUR 0.0293, implying downside of -31.74%. Forecasts are model-based projections and not guarantees. A cautious upside scenario could target EUR 0.0500 if operational turnaround and liquidity improve.

Risks, catalysts and what to watch next

Key risks include continued negative EPS, tight liquidity, and limited trading depth on XETRA that can magnify moves. Catalysts that could stabilise the stock are stronger order wins for plasma systems, successful asset recycling contracts, or capital raises that improve working capital. Monitor cash per share 0.0017, days sales outstanding 143 and any corporate updates on the company website and exchange filings.

Final Thoughts

1EZ0.F stock finished the market-closed session on 18 Feb 2026 at EUR 0.0293, down 15.56%, a move driven by thin volume and weak fundamentals. Our review shows negative margins, heavy depreciation versus historical averages and solvency pressure with a current ratio below 1.0. Meyka AI rates 1EZ0.F at 62.87 out of 100 (Grade B, HOLD) while warning that third-party aggregator ratings show sell pressure. Meyka AI’s forecast model projects a base 12-month target of EUR 0.0200, implying -31.74% from EUR 0.0293; that projection highlights downside risk if operational metrics do not improve. For investors, this is a high-volatility, speculative situation: only consider exposure with strict position sizing, stop-loss discipline and close monitoring of liquidity and company updates. Meyka AI provides this as AI-powered market analysis; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.